The precursor to BioCurate was launched in June 2016 with the ‘working title’ of M2 Venture Catalyst. Since then, BioCurate Pty Ltd has been incorporated and is on track to commence operations in early 2017.
A Bold New Venture
For the Development of New Medicines
In order to realise the full potential of Australia’s innovation opportunities, new approaches are required to take discoveries through the process of translation and early commercialisation - the so-called ‘valley of death’.
It is precisely this ‘valley’ that a newly launched $80 million enterprise, BioCurate Pty Ltd, aims to traverse in the field of biomedical drug development.
BioCurate has been formed as a joint venture between two leading Australian Universities, the University of Melbourne and Monash University.
As an independent venture catalyst, BioCurate will target this critical phase of development and provide the commercial focus, expertise and funding, necessary to boost successful translation and commercialisation.